Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | EDNRB | P24530 | 3/20 | 0.45 |
| ▸ | EDNRA | P25101 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11362484 | 0.88 | PLK1 (0.69) | PLK1ALDH1A1SMN1; SMN2EDNRBEDNRA | |
| SCHEMBL4938172 | 0.86 | PLK1 (0.55) | PLK1ALDH1A1CYP3A4SMN1; SMN2ESR1 | |
| SCHEMBL4712109 | 0.86 | PLK1 (0.55) | PLK1ALDH1A1CYP3A4SMN1; SMN2ESR1 | |
| SCHEMBL1464754 | 0.84 | PLK1 (0.57) | PLK1ALDH1A1CYP3A4SMN1; SMN2ESR1 | |
| SCHEMBL5743163 | 0.82 | CYP3A4 (0.55) | PLK1ALDH1A1CYP3A4SMN1; SMN2ESR1 | |
| SCHEMBL10608873 | 0.80 | KMT2A (0.62) | PLK1ALDH1A1CYP3A4SMN1; SMN2ESR1 | |
| SCHEMBL14040918 | 0.76 | MAPT (0.56) | PLK1ALDH1A1CYP3A4SMN1; SMN2ESR1 | |
| SCHEMBL10610633 | 0.76 | MEN1 (0.61) | PLK1ALDH1A1CYP3A4SMN1; SMN2ESR1 | |
| SCHEMBL14337774 | 0.75 | CYP3A4 (0.57) | ALDH1A1CYP3A4SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8144226 | 0.75 | CYP3A4 (0.57) | ALDH1A1CYP3A4SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524744-B2 | preventing and/or treating the diseases related to the plaque-activating factors, especially in anti-inflammation and immunization, more especially in the treatment of the acute or chronic inflammation, such as, osteoarthritis, oarthritis deformans, etc. | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-09-03 | — | — | US | disclosed |
| US-20080221106-A1 | Arylamine Ketones, Their Preparation Methods, The Pharmaceutical Composition Containing Them And Their Use | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2008-09-11 | — | — | US | disclosed |
| EP-1783115-A1 | ARYLAMINE KETONES, THEIR PREPARATION METHODS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221106-A1 | Arylamine Ketones, Their Preparation Methods, The Pharmaceutical Composition Containing Them And Their Use | AHR, KYNU, AADAC | PLK1 4648/4885ALDH1A1 854/4885CYP3A4 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.